Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. (Q54571851)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Carlo Barone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Michele Basso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Giovanni Schinzari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Nunziatina Trigila

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ettore D'Argento

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Michela Quirino

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Antonio Astone

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Alessandra Cassano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

25 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

104-111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577620%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10120-007-0415-x

1 January 2020

exact match

0 references

cites work

Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-007-0415-X

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-007-0415-X

In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

12 December 2020

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

1 reference

12 December 2020

Treatment of localized gastric cancer

1 reference

12 December 2020

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

1 reference

12 December 2020

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

12 December 2020

Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma

1 reference

12 December 2020

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

12 December 2020

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

12 December 2020

Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.

1 reference

12 December 2020

Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin

1 reference

12 December 2020

A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer

1 reference

12 December 2020

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

12 December 2020

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

1 reference

12 December 2020

New designs for the selection of treatments to be tested in randomized clinical trials

1 reference

12 December 2020

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

1 reference

12 December 2020

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

12 December 2020

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

12 December 2020

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

12 December 2020

Gastric cancer epidemiology and risk factors

1 reference

12 December 2020

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

12 December 2020

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

1 reference

12 December 2020

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

12 December 2020

Global cancer statistics in the year 2000.

1 reference

12 December 2020

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer

1 reference

12 December 2020

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

12 December 2020

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

12 December 2020

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

1 reference

12 December 2020